Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication
N-[(2S)-1-[[(3S)-1-(benzenesulfonyl)-5-phenylpentan-3-yl]amino]-1-oxo-3-phenylpropan-2-yl]-4-methylpiperazine-1-carboxamide
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/31/2021
MXB-9
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/31/2021
MXB-4
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/31/2021
rLVS ΔcapB/SCoV2 MN
Potential treatment - pre-clinical evidence Experimental Vaccine Mar/30/2021
FC05
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/29/2021
P17
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/29/2021
H014
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/29/2021
HB27
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/29/2021
Full-length Spike protein
Potential treatment - pre-clinical evidence Experimental Vaccine Mar/29/2021
SinaCurcumin®
Potential treatment - clinical evidence Experimental Antiviral Mar/28/2021
BBV152
Emergency use authorization Experimental Vaccine Mar/27/2021
Aloxistatin
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/27/2021
3,3'-(Biphenyl-4,4'-diyldidiazene-2,1-diyl)bis(4-aminonaphthalene-1-sulfonic acid)
Potential treatment - theoretical effect Experimental Antiviral Mar/26/2021
Mefuparib hydrochloride
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/26/2021
CoV-X2
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/25/2021
Torin 2
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/25/2021
Vistusertib
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/25/2021
Galidesivir
Potential treatment - theoretical effect Experimental Antiviral Mar/25/2021
mAb2
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/24/2021
mAb8
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/24/2021